Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain.
Identifieur interne : 002831 ( PubMed/Corpus ); précédent : 002830; suivant : 002832Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain.
Auteurs : Ling Ni ; Jieqing Zhu ; Junjie Zhang ; Meng Yan ; George F. Gao ; Po TienSource :
- Biochemical and biophysical research communications [ 0006-291X ] ; 2005.
English descriptors
- KwdEn :
- Cell Line, Circular Dichroism, Electrophoresis, Polyacrylamide Gel, Humans, Membrane Fusion (drug effects), Membrane Glycoproteins (antagonists & inhibitors), Recombinant Proteins (pharmacology), SARS Virus (physiology), Spike Glycoprotein, Coronavirus, Viral Envelope Proteins (antagonists & inhibitors).
- MESH :
- chemical , antagonists & inhibitors : Membrane Glycoproteins, Viral Envelope Proteins.
- drug effects : Membrane Fusion.
- chemical , pharmacology : Recombinant Proteins.
- physiology : SARS Virus.
- Cell Line, Circular Dichroism, Electrophoresis, Polyacrylamide Gel, Humans, Spike Glycoprotein, Coronavirus.
Abstract
Entry of SARS-CoV into a target cell is initiated by binding of the S1 domain of spike protein to a receptor, followed by conformational changes of the spike protein S2 domain, resulting in the formation of a six-helix bundle by the heptad-repeat (HR1 and HR2) regions. Our previous studies have demonstrated that peptides derived from HR2 region could inhibit SARS-CoV entry. However, synthesis of these peptides is at high cost. In this study, we designed two recombinant proteins, one containing two HR1 and one HR2 peptides (denoted HR121), and the other consisting of two HR2 and one HR1 peptides (designated HR212). These two proteins could be easily purified with the low cost of production, exhibiting high stability and potent inhibitory activity on entry of the HIV/SARS pseudoviruses with IC(50) values of 4.13 and 0.95muM, respectively. These features suggest that HR121 and HR212 can serve as potent inhibitors of SARS-CoV entry.
DOI: 10.1016/j.bbrc.2005.02.117
PubMed: 15781229
Links to Exploration step
pubmed:15781229Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain.</title><author><name sortKey="Ni, Ling" sort="Ni, Ling" uniqKey="Ni L" first="Ling" last="Ni">Ling Ni</name><affiliation><nlm:affiliation>Department of Molecular Virology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100080, PR China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhu, Jieqing" sort="Zhu, Jieqing" uniqKey="Zhu J" first="Jieqing" last="Zhu">Jieqing Zhu</name></author><author><name sortKey="Zhang, Junjie" sort="Zhang, Junjie" uniqKey="Zhang J" first="Junjie" last="Zhang">Junjie Zhang</name></author><author><name sortKey="Yan, Meng" sort="Yan, Meng" uniqKey="Yan M" first="Meng" last="Yan">Meng Yan</name></author><author><name sortKey="Gao, George F" sort="Gao, George F" uniqKey="Gao G" first="George F" last="Gao">George F. Gao</name></author><author><name sortKey="Tien, Po" sort="Tien, Po" uniqKey="Tien P" first="Po" last="Tien">Po Tien</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15781229</idno><idno type="pmid">15781229</idno><idno type="doi">10.1016/j.bbrc.2005.02.117</idno><idno type="wicri:Area/PubMed/Corpus">002831</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002831</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain.</title><author><name sortKey="Ni, Ling" sort="Ni, Ling" uniqKey="Ni L" first="Ling" last="Ni">Ling Ni</name><affiliation><nlm:affiliation>Department of Molecular Virology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100080, PR China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhu, Jieqing" sort="Zhu, Jieqing" uniqKey="Zhu J" first="Jieqing" last="Zhu">Jieqing Zhu</name></author><author><name sortKey="Zhang, Junjie" sort="Zhang, Junjie" uniqKey="Zhang J" first="Junjie" last="Zhang">Junjie Zhang</name></author><author><name sortKey="Yan, Meng" sort="Yan, Meng" uniqKey="Yan M" first="Meng" last="Yan">Meng Yan</name></author><author><name sortKey="Gao, George F" sort="Gao, George F" uniqKey="Gao G" first="George F" last="Gao">George F. Gao</name></author><author><name sortKey="Tien, Po" sort="Tien, Po" uniqKey="Tien P" first="Po" last="Tien">Po Tien</name></author></analytic><series><title level="j">Biochemical and biophysical research communications</title><idno type="ISSN">0006-291X</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cell Line</term><term>Circular Dichroism</term><term>Electrophoresis, Polyacrylamide Gel</term><term>Humans</term><term>Membrane Fusion (drug effects)</term><term>Membrane Glycoproteins (antagonists & inhibitors)</term><term>Recombinant Proteins (pharmacology)</term><term>SARS Virus (physiology)</term><term>Spike Glycoprotein, Coronavirus</term><term>Viral Envelope Proteins (antagonists & inhibitors)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Membrane Fusion</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cell Line</term><term>Circular Dichroism</term><term>Electrophoresis, Polyacrylamide Gel</term><term>Humans</term><term>Spike Glycoprotein, Coronavirus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Entry of SARS-CoV into a target cell is initiated by binding of the S1 domain of spike protein to a receptor, followed by conformational changes of the spike protein S2 domain, resulting in the formation of a six-helix bundle by the heptad-repeat (HR1 and HR2) regions. Our previous studies have demonstrated that peptides derived from HR2 region could inhibit SARS-CoV entry. However, synthesis of these peptides is at high cost. In this study, we designed two recombinant proteins, one containing two HR1 and one HR2 peptides (denoted HR121), and the other consisting of two HR2 and one HR1 peptides (designated HR212). These two proteins could be easily purified with the low cost of production, exhibiting high stability and potent inhibitory activity on entry of the HIV/SARS pseudoviruses with IC(50) values of 4.13 and 0.95muM, respectively. These features suggest that HR121 and HR212 can serve as potent inhibitors of SARS-CoV entry.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15781229</PMID><DateCompleted><Year>2005</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-291X</ISSN><JournalIssue CitedMedium="Print"><Volume>330</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Apr</Month><Day>29</Day></PubDate></JournalIssue><Title>Biochemical and biophysical research communications</Title><ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation></Journal><ArticleTitle>Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain.</ArticleTitle><Pagination><MedlinePgn>39-45</MedlinePgn></Pagination><Abstract><AbstractText>Entry of SARS-CoV into a target cell is initiated by binding of the S1 domain of spike protein to a receptor, followed by conformational changes of the spike protein S2 domain, resulting in the formation of a six-helix bundle by the heptad-repeat (HR1 and HR2) regions. Our previous studies have demonstrated that peptides derived from HR2 region could inhibit SARS-CoV entry. However, synthesis of these peptides is at high cost. In this study, we designed two recombinant proteins, one containing two HR1 and one HR2 peptides (denoted HR121), and the other consisting of two HR2 and one HR1 peptides (designated HR212). These two proteins could be easily purified with the low cost of production, exhibiting high stability and potent inhibitory activity on entry of the HIV/SARS pseudoviruses with IC(50) values of 4.13 and 0.95muM, respectively. These features suggest that HR121 and HR212 can serve as potent inhibitors of SARS-CoV entry.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Molecular Virology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100080, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jieqing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Junjie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Meng</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>George F</ForeName><Initials>GF</Initials></Author><Author ValidYN="Y"><LastName>Tien</LastName><ForeName>Po</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochem Biophys Res Commun</MedlineTA><NlmUniqueID>0372516</NlmUniqueID><ISSNLinking>0006-291X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008561" MajorTopicYN="N">Membrane Fusion</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>02</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>3</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>5</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>3</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15781229</ArticleId><ArticleId IdType="pii">S0006-291X(05)00392-X</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2005.02.117</ArticleId><ArticleId IdType="pmc">PMC7092889</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15150417</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biophys J. 2000 Feb;78(2):886-900</Citation><ArticleIdList><ArticleId IdType="pubmed">10653801</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2004 May 14;279(20):20836-49</Citation><ArticleIdList><ArticleId IdType="pubmed">14996844</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1995-2005</Citation><ArticleIdList><ArticleId IdType="pubmed">12671061</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2004 Nov 19;279(47):49414-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15345712</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Acta Crystallogr D Biol Crystallogr. 2003 Jul;59(Pt 7):1296-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12832792</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Nov;78(22):12557-65</Citation><ArticleIdList><ArticleId IdType="pubmed">15507643</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Annu Rev Biochem. 2001;70:777-810</Citation><ArticleIdList><ArticleId IdType="pubmed">11395423</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 1997 Jul 17;388(6639):296-300</Citation><ArticleIdList><ArticleId IdType="pubmed">9230441</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1977-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2002 Dec 20;299(5):897-902</Citation><ArticleIdList><ArticleId IdType="pubmed">12470664</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Jun;78(11):5642-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15140961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Jul 26;362(9380):263-70</Citation><ArticleIdList><ArticleId IdType="pubmed">12892955</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Arch Virol. 2003 Jul;148(7):1301-16</Citation><ArticleIdList><ArticleId IdType="pubmed">12827462</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jul 2;319(3):746-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15184046</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>AIDS Res Hum Retroviruses. 1989 Aug;5(4):431-40</Citation><ArticleIdList><ArticleId IdType="pubmed">2788443</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Oral Dis. 2004 Nov;10(6):327-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15533206</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Membr Biol. 1999 Jan-Mar;16(1):3-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10332732</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Jul;78(13):6938-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15194770</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2002 Oct 10;302(1):174-84</Citation><ArticleIdList><ArticleId IdType="pubmed">12429526</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Arch Biochem Biophys. 2004 Jan 1;421(1):143-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14678795</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jun 18;319(1):283-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15158473</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Mar 5;315(2):439-44</Citation><ArticleIdList><ArticleId IdType="pubmed">14766227</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Mol Biol. 1999 Jul 30;290(5):1031-41</Citation><ArticleIdList><ArticleId IdType="pubmed">10438601</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2004 Mar 20;363(9413):938-47</Citation><ArticleIdList><ArticleId IdType="pubmed">15043961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Annu Rev Biochem. 2000;69:531-69</Citation><ArticleIdList><ArticleId IdType="pubmed">10966468</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2004 May;16(5):277-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15132791</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 Nov 28;302(5650):1504-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14645828</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2003 Aug;77(16):8801-11</Citation><ArticleIdList><ArticleId IdType="pubmed">12885899</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002831 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002831 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15781229
|texte= Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15781229" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |